These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15520004)

  • 1. Distinct molecular mechanisms for agonist peptide binding to types A and B cholecystokinin receptors demonstrated using fluorescence spectroscopy.
    Harikumar KG; Clain J; Pinon DI; Dong M; Miller LJ
    J Biol Chem; 2005 Jan; 280(2):1044-50. PubMed ID: 15520004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor.
    Harikumar KG; Pinon DI; Wessels WS; Prendergast FG; Miller LJ
    J Biol Chem; 2002 May; 277(21):18552-60. PubMed ID: 11893747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fluorescence resonance energy transfer analysis of the antagonist- and partial agonist-occupied states of the cholecystokinin receptor.
    Harikumar KG; Miller LJ
    J Biol Chem; 2005 May; 280(19):18631-5. PubMed ID: 15757907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of probes with fluorescence indicator distributed throughout the pharmacophore to examine the peptide agonist-binding environment of the family B G protein-coupled secretin receptor.
    Harikumar KG; Hosohata K; Pinon DI; Miller LJ
    J Biol Chem; 2006 Feb; 281(5):2543-50. PubMed ID: 16319066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluorescence characteristics of hydrophobic partial agonist probes of the cholecystokinin receptor.
    Harikumar KG; Pinon DI; Miller LJ
    Biosci Rep; 2006 Apr; 26(2):89-100. PubMed ID: 16779661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of modification of membrane cholesterol and sphingolipids on the conformation, function, and trafficking of the G protein-coupled cholecystokinin receptor.
    Harikumar KG; Puri V; Singh RD; Hanada K; Pagano RE; Miller LJ
    J Biol Chem; 2005 Jan; 280(3):2176-85. PubMed ID: 15537636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fluorescent indicators distributed throughout the pharmacophore of cholecystokinin provide insights into distinct modes of binding and activation of type A and B cholecystokinin receptors.
    Harikumar KG; Pinon DI; Miller LJ
    J Biol Chem; 2006 Sep; 281(37):27072-80. PubMed ID: 16857665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Measurement of intermolecular distances for the natural agonist Peptide docked at the cholecystokinin receptor expressed in situ using fluorescence resonance energy transfer.
    Harikumar KG; Pinon DI; Wessels WS; Dawson ES; Lybrand TP; Prendergast FG; Miller LJ
    Mol Pharmacol; 2004 Jan; 65(1):28-35. PubMed ID: 14722234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
    J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Fluorescence Indicators in Receptor Ligands.
    Harikumar KG; Miller LJ
    Methods Mol Biol; 2015; 1335():115-30. PubMed ID: 26260598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Key differences in molecular complexes of the cholecystokinin receptor with structurally related peptide agonist, partial agonist, and antagonist.
    Arlander SJ; Dong M; Ding XQ; Pinon DI; Miller LJ
    Mol Pharmacol; 2004 Sep; 66(3):545-52. PubMed ID: 15322246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structurally related peptide agonist, partial agonist, and antagonist occupy a similar binding pocket within the cholecystokinin receptor. Rapid analysis using fluorescent photoaffinity labeling probes and capillary electrophoresis.
    Dong M; Ding XQ; Pinon DI; Hadac EM; Oda RP; Landers JP; Miller LJ
    J Biol Chem; 1999 Feb; 274(8):4778-85. PubMed ID: 9988716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct identification of a second distinct site of contact between cholecystokinin and its receptor.
    Hadac EM; Pinon DI; Ji Z; Holicky EL; Henne RM; Lybrand TP; Miller LJ
    J Biol Chem; 1998 May; 273(21):12988-93. PubMed ID: 9582333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The biologically crucial C terminus of cholecystokinin and the non-peptide agonist SR-146,131 share a common binding site in the human CCK1 receptor. Evidence for a crucial role of Met-121 in the activation process.
    Escrieut C; Gigoux V; Archer E; Verrier S; Maigret B; Behrendt R; Moroder L; Bignon E; Silvente-Poirot S; Pradayrol L; Fourmy D
    J Biol Chem; 2002 Mar; 277(9):7546-55. PubMed ID: 11724786
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of two amino acids of the human cholecystokinin-A receptor that interact with the N-terminal moiety of cholecystokinin.
    Kennedy K; Gigoux V; Escrieut C; Maigret B; Martinez J; Moroder L; Fréhel D; Gully D; Vaysse N; Fourmy D
    J Biol Chem; 1997 Jan; 272(5):2920-6. PubMed ID: 9006937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct identification of a distinct site of interaction between the carboxyl-terminal residue of cholecystokinin and the type A cholecystokinin receptor using photoaffinity labeling.
    Ji Z; Hadac EM; Henne RM; Patel SA; Lybrand TP; Miller LJ
    J Biol Chem; 1997 Sep; 272(39):24393-401. PubMed ID: 9305898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential docking of high-affinity peptide ligands to type A and B cholecystokinin receptors demonstrated by photoaffinity labeling.
    Dong M; Liu G; Pinon DI; Miller LJ
    Biochemistry; 2005 May; 44(17):6693-700. PubMed ID: 15850403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.
    Weng JH; Blommaert AG; Moizo L; Bado A; Ducos B; Böhme A; Garbay C; Roques BP
    Bioorg Med Chem; 1996 Apr; 4(4):563-73. PubMed ID: 8735845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conformational analysis of possible biologically active (receptor-bound) conformations of peptides derived from cholecystokinin, cerulein and little gastrin and the opiate peptide, Met-enkephalin.
    Pincus MR; Murphy RB; Carty RP; Chen J; Shah D; Scheraga HA
    Peptides; 1988; 9 Suppl 1():145-52. PubMed ID: 2856638
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.